Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States

PURPOSE: To estimate the cost-effectiveness of Nefecon in addition to the best supportive care (BSC) vs BSC in a hypothetical cohort of commercially insured adult patients with primary immunoglobulin A nephropathy (IgAN) from a United States (US) societal perspective. METHODS: A lifetime horizon, se...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramjee, Lauren, Vurgun, Nesrin, Ngai, Christopher, Patel, Mit, Tremblay, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067365/
https://www.ncbi.nlm.nih.gov/pubmed/37020570
http://dx.doi.org/10.2147/CEOR.S389456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067365/
https://www.ncbi.nlm.nih.gov/pubmed/37020570
http://dx.doi.org/10.2147/CEOR.S389456

Ejemplares similares